Genenta Science S.p.A. GNTA
Set alert
As of Nov 2, 9:36 AM ET
- YTD
- -54.03%
- 1 year
- -76.13%
- Open
- 0.6611
- Prev close
- 0.6003
- Mkt cap
- 32.79M
- Vol
- 467.11K
- Avg vol
- 53.01K
- EPS
- -0.37
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.6611
- High
- 0.6801
- Forward P/E
- -7.53
- Beta
- 0.74
- Short ratio
- 0.19
- Inst. own
- 7.78%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.18
- 200-d avg
- 4.10
- 1y target
- 21.65
Key statistics
- Market cap
- 89.57M
- Enterprise value
- 74.75M
- Trailing P/E
- 0.00
- Forward P/E
- -7.53
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.33
- EPS (TTM)
- -0.51
- Beta
- 0.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.45M
- Total cash
- 16.91M
- Total debt
- 21.00K
- Return on equity
- -42.89%
- Shares outstanding
- 18.29M
- Short % of float
- 0.01%
- 50-day average
- 5.18
- 200-day average
- 4.10
Analyst view
Consensus: none
- Target (low)
- 19.80
- Target (mean)
- 21.65
- Target (high)
- 23.51
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Feb 8, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Jan 5, 2023 | EF Hutton | init | — | Buy |
| Jul 25, 2022 | HC Wainwright & Co. | init | — | Buy |
| Jan 13, 2022 | Maxim Group | init | — | Buy |
About Genenta Science S.p.A.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Italy
- Website
- genenta.com
News
- Genenta Science Will Do Business As Saentra Forge, With Its ADSs Trading On The Nasdaq Capital Market Under New Ticker Symbol 'SAEN,' Effective November 4
- Genenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial Platform
- Genenta Science Receives Nasdaq Noncompliance Notice, Gets Time Through April 14, 2027 To Regain Compliance
- Genenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency Notification
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit
- Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm
- Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
Your note
Sign in to keep a note on GNTA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alti Global, Inc. | 1.10% | 200,288 | 980.83K | Sep 29, 2024 |
| Algebris (UK) LTD | 0.25% | 45,000 | 220.37K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 1,862 | 9.12K | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 500 | 2.45K | Sep 29, 2024 |